Lupus & antiphospholipid syndrome
Efficacy and safety of Belimumab, Rituximab and Voclosporin in the treatment of lupus nephritis based on registered clinical trials: A systematic review and network meta-analysis
Pooled result · Complete renal remissionResult — go to the resultOR for complete renal remission 3.2 95% CI 1.41,7.24Authors' conclusion
Voclosporin and Belimumab showed significant clinical efficacy in the treatment of lupus nephritis, and the safety was not statistically different from placebo. Voclosporin had significantly better clinical efficacy than Rituximab during 1-year treatment period. Increasing the dose of Voclosporin did not significantly improve the efficacy, but it will increase the safety risk of adverse events.
Study context
- Population
- Registered RCTs of Belimumab, Rituximab and Voclosporin in LN
- Participants
- 1,212 participants5 RCTs
- Comparison
- Belimumab, Rituximab and Voclosporin vs placebo and vs each other in LN
- Outcome
- Complete renal remission
Methodological detailsregistered RCTs
- Registered RCTs
Pooled result
As reported in the abstract
OR for complete renal remission
3.2
95% CI 1.41,7.24
Voclosporin-1 yearvs Rituximab-1 year
OR for complete renal remission 3.2 (95% CI 1.41,7.24)
Safety
| Outcome | OR (95% CI) | |
|---|---|---|
| Safety (adverse events)Placebovs High-Voclosporin-1 yearStatistically significant | 0.23 (0.07,0.82) | |
| 0.050.21520Odds ratio (log scale) |
Serious adverse events
- No significant difference in incidence
Original publication
Efficacy and safety of Belimumab, Rituximab and Voclosporin in the treatment of lupus nephritis based on registered clinical trials: A systematic review and network meta-analysis. Lupus. Published 5 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →